Hu Kun, Sonti Shilpa, Glaser Sherrye T, Duclos Richard I, Gatley Samuel J
Department of Pharmaceutical Sciences, Northeastern University, 360 Huntington Avenue, Boston, MA 02115; Department of Biological Sciences, Kingsborough Community College, 2001 Oriental Boulevard, Brooklyn, NY 11235.
Department of Pharmaceutical Sciences, Northeastern University, 360 Huntington Avenue, Boston, MA 02115; Department of Biological Sciences, Kingsborough Community College, 2001 Oriental Boulevard, Brooklyn, NY 11235.
Nucl Med Biol. 2017 Feb;45:43-50. doi: 10.1016/j.nucmedbio.2016.11.001. Epub 2016 Nov 9.
Anandamide (N-arachidonoylethanolamine) is a retrograde neuromodulator that activates cannabinoid receptors. The concentration of anandamide in the brain is controlled by fatty acid amide hydrolase (FAAH), which has been the focus of recent drug discovery efforts. Previous studies in C57BL/6 mice using [H-arachidonoyl]anandamide demonstrated deposition of tritium in thalamus and cortical areas that was blocked by treatment with an FAAH inhibitor and that was not seen in FAAH-knockout mice. This suggested that long chain fatty acid amides radiolabeled in the fatty acid moiety might be useful as ex vivo and in vivo radiotracers for FAAH, since labeled fatty acid released by hydrolysis would be rapidly incorporated into phospholipids with long metabolic turnover periods.
Radiotracers were administered intravenously to conscious Swiss-Webster mice, and radioactivity concentrations in brain areas was quantified and radiolabeled metabolites determined by radiochromatography.
[C]Arachidonic acid, [C-arachidonoyl]anandamide and [C-ethanolamine]anandamide, and also [C]myristic acid, [C-myristoyl]myristoylethanolamine and [C-ethanolamine]myristoyl-ethanolamine all had very similar distribution patterns, with whole brain radioactivity concentrations of 2-4% injected dose per gram. Pretreatment with the potent selective FAAH inhibitor URB597 did not significantly alter distribution patterns although radiochromatography demonstrated that the rate of incorporation of label from [C]anandamide into phospholipids was decreased. Pretreatment with the muscarinic agonist arecoline which increases cerebral perfusion increased brain uptake of radiolabel from [C]arachidonic acid and [C-ethanolamine]anandamide, and (in dual isotope studies) from the unrelated tracer [I]RTI-55.
Together with our previously published study with [F-palmitoyl]16-fluoro-palmitoylethanolamine, the data show that the primary determinant of brain uptake for these tracers in Swiss-Webster mice is initial distribution according to blood flow. It is possible that recently reported strain differences in long chain fatty acid trafficking between C57BL/6 and Swiss-Webster mice are responsible for the differences between our results using [C]anandamide and the earlier studies using [H]anandamide.
花生四烯酸乙醇胺(N-花生四烯酰基乙醇胺)是一种能激活大麻素受体的逆行神经调质。大脑中花生四烯酸乙醇胺的浓度受脂肪酸酰胺水解酶(FAAH)控制,该酶一直是近期药物研发工作的重点。此前在C57BL/6小鼠中使用[H-花生四烯酰基]花生四烯酸乙醇胺的研究表明,氚在丘脑和皮质区域沉积,这种沉积可被FAAH抑制剂处理阻断,且在FAAH基因敲除小鼠中未观察到。这表明在脂肪酸部分进行放射性标记的长链脂肪酸酰胺可能作为FAAH的离体和体内放射性示踪剂有用,因为水解释放的标记脂肪酸会迅速掺入代谢周转期长的磷脂中。
将放射性示踪剂静脉注射给清醒的瑞士-韦伯斯特小鼠,定量脑区放射性浓度,并通过放射色谱法测定放射性标记代谢物。
[C]花生四烯酸、[C-花生四烯酰基]花生四烯酸乙醇胺和[C-乙醇胺]花生四烯酸乙醇胺,以及[C]肉豆蔻酸、[C-肉豆蔻酰基]肉豆蔻酰乙醇胺和[C-乙醇胺]肉豆蔻酰乙醇胺都有非常相似的分布模式,全脑放射性浓度为每克注射剂量的2 - 4%。用强效选择性FAAH抑制剂URB597预处理并未显著改变分布模式,尽管放射色谱法表明[C]花生四烯酸乙醇胺中标记掺入磷脂的速率降低。用增加脑灌注的毒蕈碱激动剂槟榔碱预处理增加了[C]花生四烯酸和[C-乙醇胺]花生四烯酸乙醇胺的脑摄取,以及(在双同位素研究中)无关示踪剂[I]RTI-55的脑摄取。
连同我们之前发表的关于[F-棕榈酰基]16-氟棕榈酰乙醇胺的研究,数据表明瑞士-韦伯斯特小鼠中这些示踪剂脑摄取的主要决定因素是根据血流的初始分布。最近报道的C57BL/6和瑞士-韦伯斯特小鼠在长链脂肪酸转运方面的品系差异可能是我们使用[C]花生四烯酸乙醇胺的结果与早期使用[H]花生四烯酸乙醇胺的研究结果之间差异的原因。